ERGOTAMINE TARTRATE | A087693 | PANGEA PHARMACEUTICALS LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Senores Pharmaceuticals, Inc. FDA-2026-P-7182 · 7 docket documents Senores Pharmaceuticals, Inc. filed a suitability petition requesting that the FDA determine whether their proposed drug substance, a new chemical entity, is suitable for inclusion in an ANDA as a reference listed drug or as an alternative reference standard for generic pharmaceutical development. T | Suitability | 2026-06-29 | Open | Senores Pharmaceuticals, Inc. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$43.16
per ea
Lowest NADAC/Unit
$43.16
per ea
Brand NDCs
0
Generic NDCs
0
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 81279010420ERGOMAR 2 MG TABLET SUBLINGUAL | $43.16 | EA | — | — | 2026-08-19 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.